Experience

StubHub Announces $800 Million IPO

September 18, 2025

Cooley advised the underwriters of StubHub Holdings, a global secondary ticketing marketplace for live events, in connection with StubHub’s $800 million initial public offering (IPO).

Read more

Related contacts

David Peinsipp
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Denny Won
Partner, San Francisco
Shannon Eagan
Partner in Charge – Palo Alto, Palo Alto
Adam Fleisher
Partner, Washington, DC
Charlie Kim
Partner, San Diego
Kevin King
Partner, Washington, DC
Xander Lee
Partner, Santa Monica
James Maton
Co-Partner in Charge – London, London
Barbara Mirza
Partner, Santa Monica
John Paul Oleksiuk
Partner, New York
Obrea Poindexter
Partner, Washington, DC
Francis Wheeler
Senior Counsel, Colorado
Chris Chynoweth
Special Counsel, New York
Sharon Connaughton
Special Counsel, Washington, DC
David Hopkins
Special Counsel, Colorado
Andrew Linch
Special Counsel, London
Kimberly Nguyen
Special Counsel, Reston
Randy Sabett
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Peter Burns
Of Counsel, Palo Alto
Chelsea André
Associate, Colorado
Jasmine A. Banks
Associate, Washington, DC
Peter A. Haddad
Associate, San Diego
David D. Kim
Associate, San Francisco
Dana N. Levin
Associate, New York
Isabelle Mackesey
Associate, Reston
Liz Paisner
Associate, New York
Erica Russell
Associate, San Francisco
Valerie Sapozhnikova
Associate, Los Angeles
Patrick Sharma
Associate, Santa Monica
Ryan Sim
Associate, San Francisco
Arda Can Tekin
Associate, London
Lawrence Traylor
Associate, Santa Monica
Genevieve Lim Urban
Associate, Seattle
Veronica Cortes
Paralegal Specialist, New York
Melissa Eskola
Paralegal Specialist, Reston
Margie Murphy
Paralegal Specialist, New York
Douglas Lyles
Senior Research Services & Access Analyst

Related Practices & Industries

Y-mAbs Therapeutics Agrees to Acquisition by SERB Pharmaceuticals

August 5, 2025

Cooley advised Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, on its definitive merger agreement with SERB Pharmaceuticals. Under the agreement, SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA, in an all-cash transaction representing an equity value of approximately $412 million.

Read more

Related contacts

Bill Sorabella
Partner, New York
Bill Roegge
Partner, New York
Div Gupta
Partner, New York
Sarah Sellers
Partner, New York
Christophe Beauduin
Partner, New York
Megan Browdie
Partner, Washington, DC
Brad Goldberg
Partner, New York
Christopher Kimball
Partner, Washington, DC
Eileen Marshall
Partner, Washington, DC
Darah Protas
Partner, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Julia Kim
Special Counsel, New York
Justin Kisner
Special Counsel, San Diego
MaryBeth Shreiner
Special Counsel, Reston
Karen Tsai
Special Counsel, Washington, DC
Amanda Weiss
Special Counsel, New York
Rajdeep Roger Bains
Associate, San Diego
Dayne Brown
Associate, New York
Norma Chayo Dichi
Associate, Washington, DC
Sharon Davidov
Associate, New York
Athina Gaki
Associate, Brussels
Kyle Hess
Associate, New York
Katie Kaufman
Associate, Boston
Nicollette R. Kirby
Associate, Washington, DC
Arda Can Tekin
Associate, London
Shaun (Tianjie) Wang
Associate, New York

Related Practices & Industries

BioNTech Announces Global Collaboration Agreement With Bristol Myers Squibb

June 3, 2025

Cooley advised BioNTech SE, a global biotechnology company pioneering next-generation immunotherapies, on its global co-development and co-commercialization collaboration agreement with Bristol Myers Squibb for BioNTech’s antibody candidate BNT327. The transaction includes a $1.5 billion upfront payment and $2 billion total in noncontingent anniversary payments through 2028.

Read more

Related contacts

Kenneth Krisko
Partner, Reston
J. Brian Stalter
Special Counsel, New York
John Forrest
Associate, Boston
Arda Can Tekin
Associate, London
Megan Browdie
Partner, Washington, DC
David Burns
Special Counsel, Washington, DC
Jonas Koponen
Partner, Brussels
Rachel Thorn
Of counsel, New York
Eric Blanchard
Partner, Boston
Christopher Kimball
Partner, Washington, DC
Joe Sandys
Special Counsel, London
Natasha Leskovsek
Of Counsel, Washington, DC
Navya Dasari
Associate, New York
Douglas Lyles
Senior Research Services & Access Analyst

Related Practices & Industries

Cooley Advises Special Committee of Checkpoint on Acquisition by Sun Pharma

March 9, 2025

Cooley advised the special committee of Checkpoint Therapeutics’ (Nasdaq: CKPT) board of directors in connection with Checkpoint’s definitive agreement to be acquired by Sun Pharmaceutical Industries (NSE: SUNPHARMA) for up to $416 million in cash and contingent value rights.

Read more

Related contacts

Bill Roegge
Partner, New York
Kevin Cooper
Partner, New York
Marc Recht
Partner, Boston
Wesley Dietrich
Associate, Washington, DC
Kathryn Benvenuti
Associate, New York
Michael Bergmann
Partner, Washington, DC
Eileen Marshall
Partner, Washington, DC
Alan W. Tamarelli
Partner, New York
Julia R. Brinton
Special Counsel, Washington, DC
Rebecca Ross
Special Counsel, Washington, DC
Stella Sarma
Partner, Brussels
Natasha Leskovsek
Of Counsel, Washington, DC
Karun Ahuja
Special Counsel, Chicago
Matthew Choy
Associate, New York
Jameson Davis
Associate, Boston
Kyle Hess
Associate, New York
Allison Kutner
Associate, New York
Breanna Qin
Associate, Palo Alto
Arda Can Tekin
Associate, London
Ryan Vann
Partner, Chicago

Related Practices & Industries

Hummingbird Bioscience Announces Exclusive Worldwide License Agreement With Callio Therapeutics

March 3, 2025

Cooley advised Hummingbird Bioscience, a Singapore-based biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases, on its exclusive worldwide license agreement with Callio Therapeutics, a newly launched biotech company focused on realizing the promise of multipayload antibody-drug conjugates (ADCs) to improve cancer therapy.

Read more

Related contacts

James Schneider
Partner, Boston
Jeffrey J. Tolin
Partner, New York
Steven Holm
Counsel, Singapore
Michael Fernando
Associate, London
Michael Bergmann
Partner, Washington, DC
Paula Holland
Partner, London
Nicola Squire
Partner, London
Yi Jia Ng
Special Counsel, Singapore
Bethan Chalmers
Associate, London
Amanda Pacheco
Associate, Palo Alto
Alexandra Paterson
Associate, London
Mara Rosario
Associate, Boston
Arda Can Tekin
Associate, London

Related Practices & Industries

Admissions and credentials

New York

England and Wales

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.